Fixed ratio dosing of pramlintide with regular insulin before a standard meal in patients with type 1 diabetes

M. C. Riddle, K. C J Yuen, T. W. de Bruin, K. Herrmann, J. Xu, P. Öhman, O. G. Kolterman

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Amylin is co-secreted with insulin and is therefore lacking in patients with type 1 diabetes. Replacement with fixed ratio co-administration of insulin and the amylin analogue pramlintide may be superior to separate dosing. This concept was evaluated in a ratio-finding study. Patients with type 1 diabetes were enrolled in a randomized, single-masked, standard breakfast crossover study using regular human insulin injected simultaneously with pramlintide 6, 9 or 12 mcg/unit insulin or placebo. Insulin dosage was reduced by 30% from patients' usual estimates. Plasma glucose, glucagon and pramlintide and adverse events were assessed. All ratios reduced 0-3-h glucose and glucagon increments by >50%. No hypoglycaemia occurred. Adverse events were infrequent and generally mild. All pramlintide/insulin ratios markedly and safely reduced glycaemic excursions and suppressed glucagon secretion in the immediate postprandial state. Further study using one of these ratios to explore the efficacy and safety of longer-term meal-time and basal hormone replacement is warranted.

Original languageEnglish (US)
Pages (from-to)904-907
Number of pages4
JournalDiabetes, Obesity and Metabolism
Volume17
Issue number9
DOIs
StatePublished - Sep 1 2015
Externally publishedYes

Fingerprint

Type 1 Diabetes Mellitus
Meals
Insulin
Glucagon
Islet Amyloid Polypeptide
Insulin, Regular, Human
Glucose
Breakfast
Hypoglycemia
Cross-Over Studies
Placebos
pramlintide
Hormones
Safety

Keywords

  • Amylin
  • Pramlintide
  • Type 1 diabetes

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Riddle, M. C., Yuen, K. C. J., de Bruin, T. W., Herrmann, K., Xu, J., Öhman, P., & Kolterman, O. G. (2015). Fixed ratio dosing of pramlintide with regular insulin before a standard meal in patients with type 1 diabetes. Diabetes, Obesity and Metabolism, 17(9), 904-907. https://doi.org/10.1111/dom.12504

Fixed ratio dosing of pramlintide with regular insulin before a standard meal in patients with type 1 diabetes. / Riddle, M. C.; Yuen, K. C J; de Bruin, T. W.; Herrmann, K.; Xu, J.; Öhman, P.; Kolterman, O. G.

In: Diabetes, Obesity and Metabolism, Vol. 17, No. 9, 01.09.2015, p. 904-907.

Research output: Contribution to journalArticle

Riddle, MC, Yuen, KCJ, de Bruin, TW, Herrmann, K, Xu, J, Öhman, P & Kolterman, OG 2015, 'Fixed ratio dosing of pramlintide with regular insulin before a standard meal in patients with type 1 diabetes', Diabetes, Obesity and Metabolism, vol. 17, no. 9, pp. 904-907. https://doi.org/10.1111/dom.12504
Riddle, M. C. ; Yuen, K. C J ; de Bruin, T. W. ; Herrmann, K. ; Xu, J. ; Öhman, P. ; Kolterman, O. G. / Fixed ratio dosing of pramlintide with regular insulin before a standard meal in patients with type 1 diabetes. In: Diabetes, Obesity and Metabolism. 2015 ; Vol. 17, No. 9. pp. 904-907.
@article{dd23cdf9c33b43229f32cccbd2ca2fed,
title = "Fixed ratio dosing of pramlintide with regular insulin before a standard meal in patients with type 1 diabetes",
abstract = "Amylin is co-secreted with insulin and is therefore lacking in patients with type 1 diabetes. Replacement with fixed ratio co-administration of insulin and the amylin analogue pramlintide may be superior to separate dosing. This concept was evaluated in a ratio-finding study. Patients with type 1 diabetes were enrolled in a randomized, single-masked, standard breakfast crossover study using regular human insulin injected simultaneously with pramlintide 6, 9 or 12 mcg/unit insulin or placebo. Insulin dosage was reduced by 30{\%} from patients' usual estimates. Plasma glucose, glucagon and pramlintide and adverse events were assessed. All ratios reduced 0-3-h glucose and glucagon increments by >50{\%}. No hypoglycaemia occurred. Adverse events were infrequent and generally mild. All pramlintide/insulin ratios markedly and safely reduced glycaemic excursions and suppressed glucagon secretion in the immediate postprandial state. Further study using one of these ratios to explore the efficacy and safety of longer-term meal-time and basal hormone replacement is warranted.",
keywords = "Amylin, Pramlintide, Type 1 diabetes",
author = "Riddle, {M. C.} and Yuen, {K. C J} and {de Bruin}, {T. W.} and K. Herrmann and J. Xu and P. {\"O}hman and Kolterman, {O. G.}",
year = "2015",
month = "9",
day = "1",
doi = "10.1111/dom.12504",
language = "English (US)",
volume = "17",
pages = "904--907",
journal = "Diabetes, Obesity and Metabolism",
issn = "1462-8902",
publisher = "Wiley-Blackwell",
number = "9",

}

TY - JOUR

T1 - Fixed ratio dosing of pramlintide with regular insulin before a standard meal in patients with type 1 diabetes

AU - Riddle, M. C.

AU - Yuen, K. C J

AU - de Bruin, T. W.

AU - Herrmann, K.

AU - Xu, J.

AU - Öhman, P.

AU - Kolterman, O. G.

PY - 2015/9/1

Y1 - 2015/9/1

N2 - Amylin is co-secreted with insulin and is therefore lacking in patients with type 1 diabetes. Replacement with fixed ratio co-administration of insulin and the amylin analogue pramlintide may be superior to separate dosing. This concept was evaluated in a ratio-finding study. Patients with type 1 diabetes were enrolled in a randomized, single-masked, standard breakfast crossover study using regular human insulin injected simultaneously with pramlintide 6, 9 or 12 mcg/unit insulin or placebo. Insulin dosage was reduced by 30% from patients' usual estimates. Plasma glucose, glucagon and pramlintide and adverse events were assessed. All ratios reduced 0-3-h glucose and glucagon increments by >50%. No hypoglycaemia occurred. Adverse events were infrequent and generally mild. All pramlintide/insulin ratios markedly and safely reduced glycaemic excursions and suppressed glucagon secretion in the immediate postprandial state. Further study using one of these ratios to explore the efficacy and safety of longer-term meal-time and basal hormone replacement is warranted.

AB - Amylin is co-secreted with insulin and is therefore lacking in patients with type 1 diabetes. Replacement with fixed ratio co-administration of insulin and the amylin analogue pramlintide may be superior to separate dosing. This concept was evaluated in a ratio-finding study. Patients with type 1 diabetes were enrolled in a randomized, single-masked, standard breakfast crossover study using regular human insulin injected simultaneously with pramlintide 6, 9 or 12 mcg/unit insulin or placebo. Insulin dosage was reduced by 30% from patients' usual estimates. Plasma glucose, glucagon and pramlintide and adverse events were assessed. All ratios reduced 0-3-h glucose and glucagon increments by >50%. No hypoglycaemia occurred. Adverse events were infrequent and generally mild. All pramlintide/insulin ratios markedly and safely reduced glycaemic excursions and suppressed glucagon secretion in the immediate postprandial state. Further study using one of these ratios to explore the efficacy and safety of longer-term meal-time and basal hormone replacement is warranted.

KW - Amylin

KW - Pramlintide

KW - Type 1 diabetes

UR - http://www.scopus.com/inward/record.url?scp=84939567424&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84939567424&partnerID=8YFLogxK

U2 - 10.1111/dom.12504

DO - 10.1111/dom.12504

M3 - Article

AN - SCOPUS:84939567424

VL - 17

SP - 904

EP - 907

JO - Diabetes, Obesity and Metabolism

JF - Diabetes, Obesity and Metabolism

SN - 1462-8902

IS - 9

ER -